Tumor Necrosis Factor-Alpha and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice

The study explored the impact of Tumor Necrosis Factor-α (TNF-α) and Interleukin-1 (IL-1) antagonists on inflammatory skin changes in mice undergoing Epidermal Growth Factor Receptor (EGFR) antibody therapy. It found that these antagonists, specifically etanercept and Kineret, alleviated skin inflammation, suggesting that TNF-α and IL-1 play roles in the inflammatory side effects of EGFR antibody treatments. While etanercept reduced inflammation by blocking an increase in plasma IL-1α, it also showed a moderate reduction in the antitumor efficacy of EGFR therapy, indicating TNF-α's potential role in enhancing antitumor effects. The findings provided a basis for developing treatments for EGFR antibody-induced skin rashes in cancer patients and highlighted the need for further research into human applications.